Head-to-head evidence
Lumateperone vs Risperidone (Risperdal)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Serotonin 5-HT2A / dopamine D1-D2 receptor · full Schizophrenia pipeline
Lumateperone · Caplyta
Marketed by Intra-Cellular Therapies and partners
NCT02469155 · Phase 3 · completed
The trial randomized participants to two lumateperone doses, placebo, or risperidone and used quadruple masking, with 696 participants enrolled. Its clinical primary endpoint, change in PANSS total score at week 6, was not met for either lumateperone dose versus placebo (p=0.972 and p=0.789), so the findings provide well-controlled but inconclusive evidence of benefit.
Next expected readout: December 2026 · NCT06482554 (registry estimate)
Risperidone (Risperdal)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
The study randomized 458 participants to double-blind risperidone or placebo, with change in the clinical PANSS score as the primary endpoint. Because the registry does not report whether this endpoint was met, the trial provides a well-controlled design but no assessable result.
Next expected readout: December 2026 · NCT06482554 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lumateperone's landscape · Risperidone (Risperdal)'s landscape